Spexis AG bags money for pivotal Phase III trial
Swiss Spexis AG has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1163 entries already.
Entries by Thomas Gabrielczyk
Novo Nordisk takes over Inversago Pharma Inc.
/in News/by Thomas GabrielczykWith a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.
Promising viral gene therapy for genetic kidney disease
/in News/by Thomas GabrielczykBritish researchers have proven that a new gene can prevent progression of hereditary kidney damage in mice.
Alianza Team invests in microbial oil maker Clean Food Group
/in News/by Thomas GabrielczykLipid, nutrition and frozen bakery specialist Allianza Team puts £900,500 into pre-Series A financing of microbial palm oil producer Clean Food Group Ltd.
More marine plastics than expected
/in News/by Thomas GabrielczykA Dutch-German team of researchers has found out that the amount of not degradable plastics is lower than estimated but that they persist for longer than previously assumed.
Sygnature Discovery Ltd acquires leading Canadian CRO
/in News/by Thomas GabrielczykBritish drug discovery specialist Sygnature Discovery Ltd has taken over Canadian NuChem Sciences Inc., one of North Americas largest discovery CROs
Enzyme foams morer active and stable
/in News/by Thomas GabrielczykResearchers at the Karlsruhe Institute of Technology (KIT) have transformed enzymes into a new form: as foams, the biocatalysts prove to be extremely stable and active.
Bavarian Nordic A/S bags US$120m for smallpox vaccine
/in News/by Thomas GabrielczykBavarian Nordic A/S will get US$120m from a contract for the manufacturing of smallpox and mpox vaccine from the US government.
Neuraxpharm pays US$650m for MS drug commercialisation
/in News/by Thomas GabrielczykTG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.
PureTech Health gets US$11.4m to advance LYT-300
/in News/by Thomas GabrielczykLSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.